PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Jemec, Gregor
TI  - PIONEER II: Adalimumab Reduces Disease Activity in Patients with HS
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 10--11
VI  - 14
IP  - 37
4099  - http://mdc.sagepub.com/content/14/37/10.short
4100  - http://mdc.sagepub.com/content/14/37/10.full
AB  - Hidradenitis suppurativa (HS) is a chronic, painful skin disease for which there is currently no approved treatment. Results from the Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa [PIONEER II; NCT01468233] show that patients with moderate-to-severe HS who are treated with adalimumab experience a clinically relevant reduction in objective disease activity and pain after 12 weeks, as discussed in this article.